Pure Global: Brazil's ANVISA Deadline Chaos - A Survival Guide for MedTech.

Last week, Brazil's ANVISA sent shockwaves through the MedTech industry by announcing a hard deadline for transitioning all medical device registrations to the new RDC 751 framework. In this episode, we break down what this sudden enforcement means for foreign manufacturers, moving beyond the headlines to reveal the hidden complexities and strategic risks. We explore why existing international dossiers, like those for CE marking, may not be enough and what specific gaps ANVISA is targeting, putting your market access in jeopardy. We examine the case of a European orthopedic implant company whose Brazilian sales were abruptly halted. Discover the critical flaw in their post-market surveillance plan that satisfied EU regulators but failed ANVISA's new, stricter review, forcing them into a costly and time-consuming remediation process. Key Takeaways for This Episode: 1. What is the number one mistake companies make when adapting their technical file for RDC 751? 2. Are your existing risk management and clinical evaluation reports truly compliant with Brazil's new requirements? 3. How can you avoid the common pitfalls that lead to registration suspension during this transition? 4. What specific labeling changes does ANVISA now require that could impact your supply chain? 5. Does your Brazil Registration Holder (BRH) have the technical expertise to defend your new dossier? 6. How will this surprise deadline impact your product launch timeline in Brazil for the next year? Don't let regulatory hurdles in Latin America derail your growth. Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline market access. From developing a robust regulatory strategy for Brazil to acting as your official in-country representative, we ensure your products meet ANVISA's demanding standards. Contact us to secure your market presence at [email protected] or visit https://pureglobal.com/ to learn more.